• Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

The First Antiobesity Medications to Simulate Human Physiology are Indicated for Long-term Treatment


"The GLP-1 receptor agonists are the first antiobesity medications that are simulating the body's natural physiology."

Obesity management expert and researcher Caroline Apovian, MD, draws a distinction between older antiobesity medications (AOMs), such as bupropion/naltrexone, phentermine/topirimate, and orlistat and those more recently approved including liraglutide and semaglutide 2.4 mg, both glucagon-like peptide-1 receptor agonists (GLP-1 RA).

Far from the mechanisms of action associated with the older medications, which Apovian describes as akin to "crude appetite suppression," the GLP-1 RAs are in effect mimicking the changes in the gut hormone millieu that result from bariatric surgery. Those procedures signficantly alter secretion patterns of pivotal gut hormones and result in sustained weight loss as high as 35%. Apovian elaborates in the conversation above.

Caroline M Apovian, MD, is a professor of medicine a Harvard Medical School and codirector of the Center for Weight Management and Wellness in the division of endocrinology, diabetes, and hypertension at Brigham and Women's Hospital in Boston, MA. Apovian is one of the founding creators of the American Board of Obesity Medicine, the body that provides certification and recognititon for physicains who have specialized knowledge and training in the practice of obesity medicine.

Related Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Document COVID Sequelae and Primary Care: An Interview with Samoon Ahmad, MD
Overweight and Obesity: One Expert's 3 Wishes for the Future of Patient Care
Donna H Ryan, MD Obesity Expert Highlights 2021 Research Success and Looks to 2022 and Beyond
Related Content
© 2024 MJH Life Sciences

All rights reserved.